

Domestic Net Sales

Three months ended March 31, 2017 and 2016 (unaudited)

DOMESTIC NET SALES: QTD				
(in millions)	Q1 2017	Q1 2016	Change	
INTERVENTIONAL CARDIOLOGY	\$ 278	\$ 238	17%	
CARDIAC RHYTHM MANAGEMENT	283	256	11%	
ENDOSCOPY	215	182	18%	
PERIPHERAL INTERVENTIONS	142	135	5%	
UROLOGY AND PELVIC HEALTH	183	161	14%	
NEUROMODULATION	116	105	10%	
ELECTROPHYSIOLOGY	32	31	3%	
TOTAL CORE BUSINESSES	\$ 1,249	\$ 1,108	13%	

Growth rates are based on actual, non-rounded amounts and may not recalculate precisely.

International Net Sales

Three months ended March 31, 2017 and 2016 (unaudited)

INTERNATIONAL NET SALES: QTD					
(in millions)	Q1 2017	Q1 2016	Change		
			As Reported	Constant Currency Basis	
INTERVENTIONAL CARDIOLOGY	\$ 312	\$ 310	1%	2%	
CARDIAC RHYTHM MANAGEMENT	180	177	1%	3%	
ENDOSCOPY	164	151	9%	9%	
PERIPHERAL INTERVENTIONS	119	107	10%	11%	
UROLOGY AND PELVIC HEALTH	79	67	18%	18%	
NEUROMODULATION	25	16	60%	60%	
ELECTROPHYSIOLOGY	32	28	13%	15%	
TOTAL CORE BUSINESSES	\$ 911	\$ 856	6%	7%	

Growth rates are based on actual, non-rounded amounts and may not recalculate precisely.

Worldwide Net Sales

Three months ended March 31, 2017 and 2016 (unaudited)

WORLDWIDE NET SALES: QTD					
(in millions)	Q1 2017	Q1 2016	Change		Constant Currency Basis
			As Reported		
INTERVENTIONAL CARDIOLOGY	\$ 590	\$ 548	8%		8%
CARDIAC RHYTHM MANAGEMENT	463	433	7%		8%
ENDOSCOPY	379	333	14%		14%
PERIPHERAL INTERVENTIONS	261	242	7%		7%
UROLOGY AND PELVIC HEALTH	262	228	15%		15%
NEUROMODULATION	141	121	17%		17%
ELECTROPHYSIOLOGY	64	59	8%		9%
TOTAL	\$ 2,160	\$ 1,964	10%		10%

Growth rates are based on actual, non-rounded amounts and may not recalculate precisely.

Use of Non-GAAP Measures

To supplement Boston Scientific's consolidated financial statements presented on a U.S. GAAP basis, the Company discloses certain non-GAAP financial measures, including regional and divisional revenue growth rates that exclude the impact of changes in foreign currency exchange rates. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States (U.S. GAAP).

To calculate regional and divisional growth rates that exclude the impact of changes in foreign currency exchange rates, the Company converts actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior period. The U.S. GAAP financial measure most directly comparable to this non-GAAP financial measure is growth rate percentages using net sales on a U.S. GAAP basis. A reconciliation of the non-GAAP financial measures included in this document to the corresponding GAAP measures is included in Boston Scientific's most recent earnings release filed with the SEC on Form 8-K. In addition, an explanation of the ways in which Boston Scientific management uses these supplemental non-GAAP measures to evaluate its business, and the substantive reasons why Boston Scientific management believes that these non-GAAP measures provide useful information to investors is included under "Use of Non-GAAP Financial Measures" in the Company's most recent earnings release filed with the SEC on Form 8-K. This additional non-GAAP financial information is not meant to be considered in isolation from or as a substitute for financial information prepared in accordance with U.S. GAAP.